Pekka Anttila, MD

Division of Hematology, Comprehensive Cancer Center, Helsinki University and Helsinki University Hospital
Helsinki Finland Papers:
155 Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
1901 Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing Allows Identification of Physiologically Distinct Sub-Clones  That Can Inform Therapeutic and Drug Development Strategies
1960 Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone – Results from the Phase 3 Optimismm Study
1975 A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines